Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,762 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Depressive Disorder, Major
Interventions: venlafaxine XR, hydrocortisone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Depressive Disorder, Major
Interventions: LY2216684, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more

Conditions: Depressive Disorder, Major
Interventions: Sirukumab 50 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 21 more

Conditions: Depression, Depressive Disorder, Depressive Disorder, Major
Interventions: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR), Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 33 more

Conditions: Major Depressive Disorder, Treatment Resistant Depression
Interventions: Personalized iTBS, Non-Personalized iTBS, Sham iTBS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 31
States / cities: Dothan, Alabama • Tucson, Arizona • Newport Beach, California + 27 more

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, Escitalopram; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Orlando, Florida • Prairie Village, Kansas • Allentown, Pennsylvania + 1 more

Conditions: Major Depression, End Stage Renal Disease
Interventions: Fluoxetine, Bupropion; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 30 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Opiate Dependence, Suicidal Ideation, Depression, Opioid Use, Opioid-Related Disorders, Opioid-use Disorder, Major Depressive Disorder
Interventions: Accelerated intermittent theta-burst stimulation (aiTBS); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Depression
Interventions: Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 48
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more

Conditions: Depression
Interventions: S-adenosyl-l-methionine, Escitalopram, Placebo; Drug
Lead sponsor: Maurizio Fava, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Depression
Interventions: Trigeminal Nerve Stimulation; Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: 5-Hydroxytryptophan 100 MG, Creatine monohydrate, placebo matched to 5-HTP, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 25 Years to 40 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Major Depressive Disorder
Interventions: Fisher Wallace Cranial Electrotherapy Stimulator Device; Device
Lead sponsor: ProofPilot; Industry
Eligibility: 21 Years and older
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression / Major Depressive Disorder, Food Insecurity
Interventions: Medically Tailored, Home-delivered Groceries, Active Comparison Group: Monthly Grocery Gift Card; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Worcester, Massachusetts

Conditions: Depressive Disorder, Major
Interventions: functional magnetic resonance imaging (fMRI); Behavioral
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Major Depressive Disorder (MDD)
Interventions: Ropanicant, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 35
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 31 more

Conditions: Major Depressive Disorder
Interventions: BHV-7000; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 66
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Cocaine Dependence, Depressive Disorder, Major
Interventions: Bupropion; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Depressive Disorder, Insomnia
Interventions: Escitalopram, Ramelteon, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: Combination use of MBCT and IV Ketamine; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Major Depressive Disorder, Anxiety Disorders
Interventions: Hydrocortisone; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Major Depressive Disorder, Suicide, Attempted
Interventions: Not listed
Lead sponsor: Van Andel Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Depression, Major Depressive Disorder, Suicidal Ideation
Interventions: Single-Pulse Transcranial Magnetic Stimulation, EEG-Synchronized Repetitive Transcranial Magnetic Stimulation (rTMS), Cognitive Behavioral Therapy (CBT), Cognitive Flexibility and Emotion Regulation Tasks; Device · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?

A Study in Adult Patients With Major Depressive Disorder

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression

Real-life Effectiveness of Vortioxetine in Depression

A Study for Participants With Major Depression

Bupropion for Depression in ESRD Patients on Hemodialysis

Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

Trigeminal Nerve Stimulation for Depression: Dose Finding

5-HTP and Creatine for Depression

Fisher Wallace Neurostimulation & Depression Study

The Medically Tailored Groceries and Mental Health Study

Neuroimaging Study for Decoding Emotional States and Identifying Neural Circuits to Disengage From Negative Thinking

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

Integrated Treatment for Cocaine and Mood Disorders - 1

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration

A Longitudinal Study of Inflammatory Pathways in Depression

RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS